Investigational drug · Phase 2
TMB-365
Also called: TMB-380, VRC07523LS, TMB-380 is also known as VRC07-523-LS
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV-1-infection, HIV -1 Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
3
Any phase or sponsor naming "TMB-365"
First trial start
2022
Jun 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TMB-365", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
- HIV -1 Infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TMB-365" as an intervention, largest first.
- HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies StudyActive, not recruiting
TaiMed Biologics Inc.Industry
NCT07215468 · 88 participants · Start Dec 16, 2025 · Primary completion May 2027
Drug: TMB-365; TMB-380 and 1 more · For: HIV -1 Infection
Sites: San Francisco, California; Fort Lauderdale, Florida; Ft. Pierce, Florida · 10 sites in all
TaiMed Biologics Inc.Industry
NCT05275998 · 51 participants · Start Jul 5, 2022 · Primary completion Nov 20, 2024
Drug: TMB-365/TMB-380 · For: HIV-1-infection
Sites: San Francisco, California; Fort Lauderdale, Florida; Ft. Pierce, Florida · 6 sites in all
TaiMed Biologics Inc.Industry
NCT04027387 · 24 participants · Start Dec 14, 2019 · Primary completion Aug 18, 2021
Drug: TMB-365 · For: HIV-1-infection
Sites: San Francisco, California; Ft. Pierce, Florida; Orlando, Florida · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics, and antiviral activity of a combination of TMB-365 and TMB-380 in people living with HIV suppressed with antiretroviral therapy in the USA: a phase 1b/2a, open-label, dose-escalation study.
Markowitz M, Lalezari JP, DeJesus E, et al. · Lancet HIV 2026
- Proof-of-Concept Development and Preclinical Evaluation of a Microarray Patch Platform for Codelivery of Multiple Broadly Neutralizing Antibodies for HIV Prevention.
Peet MM, Agrahari V, Singh P, et al. · Mol Pharm 2026
- Distinct amino acid signatures and neutralization sensitivity of plasma- and CSF-derived HIV-1 subtype C clones.
Mtanjana S, Gumede N, Zikhali N, et al. · Retrovirology 2026
- Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trial.
Mahomed S, Paez CA, Huang Y, et al. · Lancet HIV 2026
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.
Rodriguez LR, Hall J, Cardozo-Ojeda EF, et al. · bioRxiv 2026
- Comment on: Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic-pharmacodynamic modelling in adults and infants.
Qiu W · J Antimicrob Chemother 2026
Also in development for HIV-1-infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
- PirmitegravirPhase 21 trial
ST Pharm Co., Ltd. · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.